YOUR RUNDOWN

Is there anything new happening with intravitreal injections?

Oh yes, a super cool thing. Genentech and Roche are working on a port delivery system.

Tell me about it.

The port is an implantable, refillable reservoir system that sits under the conjunctiva in the pars plana and is designed to gradually release ranibizumab (Lucentis). Here is a picture to help visualize that. The device requires a relatively simple surgical procedure (done in the OR) to be implanted, and the port is refilled as an in-office procedure using a special needle.

Who is this port for?

It's in phase 3 trials in two groups of patients: 1) patients with diabetes and macular edema and 2) patients with wet AMD.

Could it be a game changer?

The system could result in a significant reduction in injections because the port allows for continuous delivery of ranibizumab, which can allow patients to potentially go several months before needing a refill of the implant. In the phase 2 trial for patients with wet AMD, nearly 80% of patients in the port arm were able to go 6 months or longer between the implant of the device and the first required refill. (via)


WHAT YOUR PATIENT MIGHT ASK YOU

Can you show me how to put in an eye drop?

I probably should. A new study found that only 3% of participants exhibited perfect eye drop technique. It was observed that 40% of patients touched the bottle to their eye and 20% of ophthalmic suspensions were not shaken before use.


SOCIAL MEDIA ROUNDUP

16 minutes.

The number of minutes physicians spend working on their EHR with each patient.

19%.

The percentage of adults who were able to correctly identify the top three causes of blindness (AMD, glaucoma, diabetic eye disease), according to a new survey.

Want to give away some old jeans?

You could upcycle them into sunglasses instead.

The "Visine killer" update.

The woman who killed her husband after poisoning him with Visine was sentenced to 25 years in prison.

See you next week!